📊 COLL Key Takeaways
Is Collegium Pharmaceutical, Inc. (COLL) a Good Investment?
Collegium Pharmaceutical demonstrates strong fundamental health with robust revenue growth of 23.6% YoY, excellent profitability metrics including 59.3% gross margin and 23.0% operating margin, and exceptional free cash flow generation at 42% FCF margin. The company maintains a fortress balance sheet with minimal leverage (0.09x Debt/Equity) and strong liquidity ratios, supported by $231.3M in cash and $327.6M in annual free cash flow.
Collegium Pharmaceutical shows strong fundamental momentum, with revenue up 23.6% year over year, solid gross and operating margins, and exceptionally strong free cash flow conversion. The balance sheet appears manageable given ample cash, low reported long-term debt, and healthy liquidity, but flat net income and declining diluted EPS suggest growth is not fully flowing through to shareholders yet.
Why Buy Collegium Pharmaceutical, Inc. Stock? COLL Key Strengths
- Revenue growth of 23.6% YoY demonstrates strong market demand and execution
- Exceptional free cash flow margin of 42% indicates efficient operations and capital allocation
- Conservative leverage with 0.09x Debt/Equity ratio and strong interest coverage of 10.4x
- Solid liquidity position with 1.57x current ratio and $231.3M cash balance
- High gross margin of 59.3% reflects strong pricing power and product mix quality
- 8 Form 4 insider filings suggest active management engagement
- Strong top-line growth with 23.6% year-over-year revenue expansion
- High cash generation, with $327.58M of free cash flow and a 42.0% FCF margin
- Healthy operating profile supported by 59.3% gross margin, 23.0% operating margin, solid liquidity, and low reported leverage
COLL Stock Risks: Collegium Pharmaceutical, Inc. Investment Risks
- Net income growth stalled at 0% YoY despite 23.6% revenue growth, suggesting margin pressure or one-time items
- Diluted EPS declined 7.0% YoY indicating share dilution or profitability challenges at bottom line
- Pharmaceutical sector subject to regulatory, patent expiration, and reimbursement risks
- ROA of 3.8% is modest for a pharmaceutical company, suggesting asset efficiency challenges
- Net income was flat year over year and diluted EPS declined 7.0%, indicating some earnings pressure despite revenue growth
- Net margin is materially lower than operating margin, suggesting below-the-line costs or other earnings drag
- Total liabilities remain high relative to equity, which limits balance-sheet flexibility if operating conditions weaken
Key Metrics to Watch
- Net income and bottom-line margin trends to determine if current pressure reverses
- Operating cash flow sustainability and free cash flow generation consistency
- Revenue growth trajectory in context of product pipeline and market competition
- Debt levels and leverage ratios given acquisition or R&D investment activity
- Net income and diluted EPS conversion relative to revenue growth
- Free cash flow sustainability and margin retention
Collegium Pharmaceutical, Inc. (COLL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 42.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
COLL Profit Margin, ROE & Profitability Analysis
COLL vs Healthcare Sector: How Collegium Pharmaceutical, Inc. Compares
How Collegium Pharmaceutical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Collegium Pharmaceutical, Inc. Stock Overvalued? COLL Valuation Analysis 2026
Based on fundamental analysis, Collegium Pharmaceutical, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Collegium Pharmaceutical, Inc. Balance Sheet: COLL Debt, Cash & Liquidity
COLL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Collegium Pharmaceutical, Inc.'s revenue has grown significantly by 152% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.29 reflects profitable operations.
COLL Revenue Growth, EPS Growth & YoY Performance
COLL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $159.3M | $2.4M | $0.27 |
| Q2 2025 | $145.3M | $2.4M | $0.34 |
| Q1 2025 | $144.9M | $2.4M | $0.07 |
| Q3 2024 | $136.7M | $9.3M | $0.27 |
| Q2 2024 | $135.5M | -$4.4M | $-0.13 |
| Q1 2024 | $144.8M | -$17.4M | $-0.51 |
| Q3 2023 | $127.0M | $457.0K | $0.01 |
| Q2 2023 | $123.5M | -$4.4M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Collegium Pharmaceutical, Inc. Dividends, Buybacks & Capital Allocation
COLL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Collegium Pharmaceutical, Inc. (CIK: 0001267565)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COLL
What is the AI rating for COLL?
Collegium Pharmaceutical, Inc. (COLL) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are COLL's key strengths?
Claude: Revenue growth of 23.6% YoY demonstrates strong market demand and execution. Exceptional free cash flow margin of 42% indicates efficient operations and capital allocation. ChatGPT: Strong top-line growth with 23.6% year-over-year revenue expansion. High cash generation, with $327.58M of free cash flow and a 42.0% FCF margin.
What are the risks of investing in COLL?
Claude: Net income growth stalled at 0% YoY despite 23.6% revenue growth, suggesting margin pressure or one-time items. Diluted EPS declined 7.0% YoY indicating share dilution or profitability challenges at bottom line. ChatGPT: Net income was flat year over year and diluted EPS declined 7.0%, indicating some earnings pressure despite revenue growth. Net margin is materially lower than operating margin, suggesting below-the-line costs or other earnings drag.
What is COLL's revenue and growth?
Collegium Pharmaceutical, Inc. reported revenue of $780.6M.
Does COLL pay dividends?
Collegium Pharmaceutical, Inc. does not currently pay dividends.
Where can I find COLL SEC filings?
Official SEC filings for Collegium Pharmaceutical, Inc. (CIK: 0001267565) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COLL's EPS?
Collegium Pharmaceutical, Inc. has a diluted EPS of $1.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is COLL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Collegium Pharmaceutical, Inc. has a BUY rating with 80% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is COLL stock overvalued or undervalued?
Valuation metrics for COLL: ROE of 20.8% (sector avg: 15%), net margin of 8.1% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy COLL stock in 2026?
Our dual AI analysis gives Collegium Pharmaceutical, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is COLL's free cash flow?
Collegium Pharmaceutical, Inc.'s operating cash flow is $329.3M, with capital expenditures of $1.7M. FCF margin is 42.0%.
How does COLL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.1% (avg: 12%), ROE 20.8% (avg: 15%), current ratio 1.57 (avg: 2).